Article

Persistent efficacy of anakinra in patients with tumor necrosis factor receptor–associated periodic syndrome

Istituto Giannina Gaslini, Genoa, Italy.
Arthritis & Rheumatology (Impact Factor: 7.87). 05/2008; 58(5):1516-20. DOI: 10.1002/art.23475
Source: PubMed

ABSTRACT To evaluate the efficacy and safety of treatment with the interleukin-1 receptor antagonist anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome (TRAPS) requiring high cumulative doses of steroids.
Four children (mean age 9.1 years [range 4-13 years]) and 1 adult (age 33 years) with TRAPS were enrolled in the study. The 3 children with cysteine mutations (C52Y, C55Y, C43R) had prolonged and frequent attacks of fever. One child with the R92Q mutation and the adult patient with the C43R mutation displayed a more chronic disease course, with fluctuating, nearly continuous symptoms and persistent elevation of acute-phase reactant levels (including serum amyloid A [SAA]). All patients were treated with anakinra (1.5 mg/kg/day).
All of the patients had a prompt response to anakinra, with disappearance of symptoms and normalization of acute-phase reactant levels, including SAA. In all pediatric patients, anakinra was withdrawn after 15 days of treatment. After a few days (mean 5.6 days [range 3-8]) a disease relapse occurred, which dramatically responded to reintroduction of anakinra. During the following period of observation (mean 11.4 months [range 4-20 months]), the patients did not experience episodes of fever or other disease-related clinical manifestations. Levels of acute-phase reactants remained in the normal range. No major adverse reactions or severe infections were observed.
Continuous treatment with anakinra effectively controlled both the clinical and laboratory manifestations in patients with TRAPS and prevented disease relapses.

Download full-text

Full-text

Available from: Antonella Meini, Dec 22, 2014
0 Followers
 · 
122 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The term 'autoinflammatory disease' was first proposed in 1999 to encompass some of the distinct clinicopathologic features of a group of monogenic conditions, characterised by recurrent episodes of inflammation, without high-titre autoantibodies or antigen-specific T cells. It was subsequently observed that several of these conditions were caused by mutations in proteins involved in the innate immune response, including, among others, components of the NLRP3 inflammasome, cytokine receptors (tumour necrosis factor receptor 1 (TNFR1)) and receptor antagonists (interleukin 1 receptor antagonist (IL-1RA)). More recently, additional mechanisms linking innate immune-mediated inflammation with a variety of cellular processes, including protein misfolding, oxidative stress and mitochondrial dysfunction, have been recognised to play a role in the pathogenesis of some monogenic autoinflammatory conditions, and also in more common diseases such as type 2 diabetes (T2D), previously perceived as a metabolic disorder, but reclassified as a chronic inflammatory condition. NLRP3 inflammasome activation is induced by islet amyloid polypeptides (IAPPs) in T2D and this condition may, in future, be more commonly treated with targeted anti-cytokine therapies. Caspase 1 activation and release of IL-1β/IL-1 family members is central to the pathogenesis of many autoinflammatory syndromes, as evidenced by the effectiveness of anti-IL-1 biologics in treating these disorders. However, many patients continue to experience symptoms of chronic inflammation, and it will be necessary to translate discoveries on the immunopathology of these conditions into more effective therapies. For example, in tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), the pathogenesis may vary with each mutation and therefore future approaches to treatment of individual patients will require a more tailored approach based on genetic and functional studies.
    Best practice & research. Clinical rheumatology 08/2012; 26(4):505-33. DOI:10.1016/j.berh.2012.07.009 · 3.06 Impact Factor
  • Source
    Amyloidosis - An Insight to Disease of Systems and Novel Therapies, 11/2011; , ISBN: 978-953-307-795-6
  • [Show abstract] [Hide abstract]
    ABSTRACT: “Autoinflammatory syndromes” is the broad name given to a group of heritable conditions that initially consisted of a group of diseases termed hereditary periodic fever syndromes. Autoinflammatory syndrome is the preferred name for these conditions, because not all of the disorders that have been added to this class of inflammatory disorde rs present with periodic febrile episodes. In contrast to autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, autoanti-bodies and antigen-specific T cells do not play a role in the pathogenesis of the autoinflammatory syndromes. Although the term autoinflammatory syndrome is now commonly used to include polygenic diseases such as Behcet's syndrome, Still's disease, and even Type 2 diabetes, this chapter addresses the monogenic autoin-flammatory syndromes. These syndromes demonstrate a Mendelian inheritance pattern, and their genetic causes have been identified. The disorders typically present in childhood. The disorders are divided into different clinical syndromes that include mixtures of clinical manifestations in the joints, the bones, the skin, the abdomen, and the lymph nodes.